IMMUNO-ONCOLOGY
Your trial CORE-powered
IMMUNO-ONCOLOGY
SOLID TUMORS
HEMATOLOGIC ONCOLOGY
Hematologic Oncology
We recognize hematologic malignancies are distinct from solid tumors and have built specific hematologic oncology teams and processes to support these studies. Our specialists understand the clinical implications of blood-based cancers, the diverse pathologies, complex assessments, sick patient population, and lab-based endpoints inherent in hematologic trials.
THE PROOF
50
%
increase in
enrollment
Click each area to learn more
IQVIA Biotech’s clinical teams have extensive experience running immuno-oncology (IO) clinical trials. Our IO expertise spans multiple treatment modalities (checkpoint inhibitors, T cell agonists, vaccines, bispecific antibodies, adoptive cell therapies, innate immune agonists) in numerous indications across hematologic malignancies and solid tumors.
You want to get the right treatments to the right patients. We are here to help you develop and execute the most efficient path through the clinic.
THE PROOF
Your oncology experts
immuno-oncology clinical trials (adoptive cell therapies, biologics, small molecules) since 2018
Solid Tumors
Therapeutic targets in solid tumors are expanding rapidly to include smaller biomarker defined patient populations. IQVIA Biotech has the geographic reach and access to essential diagnostic and lab data to identify the right genetically defined patients for your trial. Our team has deep experience executing checkpoint inhibitor combination trials across many indications, including breast, ovarian, prostate, lung, colon and gastric cancers.
Additionally, we are supporting studies working in the exciting new area of radioligand therapy (RLT), a promising treatment modality for advanced cancers. Our team understands the complexities of site and patient management as well as the time critical IP logistics related to RLT.
THE PROOF
Immuno-Oncology
Oncology
clinical trials
Through our CORE-powered approach to cardiovascular development, IQVIA can help you rethink old challenges and surround your trials with a proven suite of capabilities to help you reach milestones faster, deliver programs within budget, and bring game-changing therapies to patients sooner.
HEMATOLOGIC ONCOLOGY
< BACK
< BACK
< BACK
IMMUNO-ONCOLOGY
SOLID TUMORS
HEMATOLOGIC ONCOLOGY
IMMUNO-ONCOLOGY
140+
Therapeutic expertise is key to ensuring you are asking the right questions, and seeing opportunities to capture new ideas, new discoveries and new approaches. Our oncology delivery team has expertise from a wide range of indications that help you connect the dots, capture best practice, and be at the forefront of discovery in oncology.
SOLID TUMORS
solid tumor clinical trials
since 2018
360+
Oncology
clinical trials
Oncology
clinical trials
HEMATOLOGIC ONCOLOGY
hematologic oncology clinical trials
since 2018
135+
of our work is in hematologic
malignancies
Immuno-Oncology
IQVIA Biotech’s clinical teams have extensive experience running immuno-oncology (IO) clinical trials. Our IO expertise spans multiple treatment modalities (checkpoint inhibitors, T cell agonists, vaccines, bispecific antibodies, adoptive cell therapies, innate immune agonists) in numerous indications across hematologic malignancies and solid tumors.
You want to get the right treatments to the right patients. We are here to help you develop and execute the most efficient path through the clinic.
THE PROOF
immuno-oncology clinical trials (adoptive cell therapies, biologics, small molecules) since 2018
